830 Morris Turnpike
Short Hills, NJ 07078-2625
973 200 3100
Full-time employees: 6
|Dr. Cameron Durrant M.D., MBA||Chairman, CEO & Acting CFO||640k||N/A||1960|
|Dr. Dale Chappell M.B.A., M.D., MBA||Chief Scientific Officer & Director||410k||N/A||1970|
|Mr. Edward P. Jordan M.B.A.||Chief Commercial Officer||364.75k||N/A||1968|
|Mr. Robert Atwill M.B.A.||Sr. VP and Head of Asia-Pacific Region & Bus. Devel.||N/A||N/A||N/A|
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
Humanigen, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.